Open Access Open Access  Restricted Access Subscription or Fee Access

A remifentanil/ketamine sedation in surgical cancer patients having severe Parkinson’s disease: Two case reports

German Salazar, MD, Cyrus Motamed, MD


Symptoms of Parkinson’s disease are related to a progressive loss of substancia nigra’s dopaminergic neurons in addition to persistent activation of N-methyl- D-aspartate receptors. In specific situations such as sedation for minor surgery, tremor and dyskinesia can be very disabling. We report the beneficial effect of the combination of remifentanil (target-controlled infusion mode) and ketamine (boluses IV) to control dyskinesia and tremor for two elderly patients with Parkinson’s disease. The patients were scheduled for elective oncological plastic surgery under sedation, for which dyskinesia and tremor needed to be quickly abolished to permit surgery. Both procedures were completed with this drug combination resulting with no major side effects.


remifentanil, ketamine, Parkinson

Full Text:



Jocoy EL, André VM, Cummings DM, et al.: Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-D-aspartate currents by dopamine D1 receptor activation in striatum. Front Syst Neurosci. 2011; 5: 28.

Dyson SC, Barker RA: Cell-based therapies for Parkinson’s disease. Expert Rev Neurother. 2011; 11(6): 831-44.

Starr MS, Starr BS, Kaur S: Stimulation of basal and L-DOPA induced motor activity by glutamate antagonists in animal models of Parkinson’s disease. Neurosci Biobehay Rev. 1997; 21: 437-446.

Justin J. Wright, Peter D. Goodnight, et al.: The utility of ketamine for the preoperative management of a patient with Parkinson’s disease. Anesth Analg. 2009; 108: 980-982.



  • There are currently no refbacks.